Journal
RHEUMATOLOGY INTERNATIONAL
Volume 31, Issue 1, Pages 89-91Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00296-009-1146-6
Keywords
Vasculitis; B cell depletion; Eosinophilia; Treatment
Categories
Ask authors/readers for more resources
Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available